NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, based on its patented NanoStat™ technology platform.
Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio’s lead product candidates target treatments for herpes labialis (cold sores), onychomycosis (nail fungus), vaginitis, cystic fibrosis and intranasal & intramuscular vaccines for influenza, RSV, HSV2 and anthrax.
Funding Rounds (6) - $82.8MUpdate
Current Team (11)Update
|Jul 27, 2016||PRNewswire All - NanoBio To Present Intranasal Pertussis Vaccine Data At The Mucosal Immunology Course & Symposium Meeting|
|Mar 24, 2016||PRNewswire All - Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles|
|Mar 18, 2016||PRNewswire UK All - Anthrax Market Pipeline Global Review Research Report for H2 2015|
|Feb 15, 2016||SEC - UNITED STATES SECURITIES AND EXCHANGE COMMISSION|
|Jan 28, 2016||PRNewswire UK All - Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies|
|Dec 17, 2015||nanobio.com - NanoBio Announces Closing of $22 Million|
|Dec 7, 2015||Business Wire - Research and Markets: Global Pertussis Therapeutics Pipeline Review, H2 2015|
|Dec 2, 2015||PRNewswire All - NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice|
2311 Green Road
Ann Arbor, Michigan 48105